Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4853029
Max Phase: Preclinical
Molecular Formula: C14H14F4N2O3
Molecular Weight: 334.27
Molecule Type: Unknown
Associated Items:
ID: ALA4853029
Max Phase: Preclinical
Molecular Formula: C14H14F4N2O3
Molecular Weight: 334.27
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H]1OC(=O)NN=C1c1ccc(OC[C@@H](C)F)c(C(F)(F)F)c1
Standard InChI: InChI=1S/C14H14F4N2O3/c1-7(15)6-22-11-4-3-9(5-10(11)14(16,17)18)12-8(2)23-13(21)20-19-12/h3-5,7-8H,6H2,1-2H3,(H,20,21)/t7-,8+/m1/s1
Standard InChI Key: CUUQUXVYSVHFQW-SFYZADRCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 334.27 | Molecular Weight (Monoisotopic): 334.0941 | AlogP: 3.27 | #Rotatable Bonds: 4 |
Polar Surface Area: 59.92 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 10.52 | CX Basic pKa: | CX LogP: 3.18 | CX LogD: 3.18 |
Aromatic Rings: 1 | Heavy Atoms: 23 | QED Weighted: 0.86 | Np Likeness Score: -0.65 |
1. Sabnis RW.. (2021) Novel Dihydrooxadiazinones as PDE3 Inhibitors for Treating Cancer., 12 (7.0): [PMID:34267873] [10.1021/acsmedchemlett.1c00317] |
Source(1):